Pharmaceuticals

US Deputy Health Secretary, Alex Azar, is lobbying the Britain's Health Secretary, Patricia Hewitt, to ease restrictions on the drug industry. In particular, the U.S. drug companies want the ban on direct-to-consumer advertising dropped and to increase the prices the government pays for drugs.

Adriane Fugh-Berman, an Associate Professor at Georgetown University School of Medicine, recounts her experience of speaking at a recent medical conference in New Mexico on the topic of drug industry influence in medical education. "Immediately after my talk, one pharmaceutical company representative announced to a conference organiser that her company would no longer support the annual conference. Another packed up his exhibit and walked out," she writes in the British Medical Journal.

In a survey of 29 U.S. patient groups, New Scientist found only two ruled out drug company funding. Seven of the patient groups surveyed received less than 5% of their income from drug companies, while others were reliant on them for over one-third of their budget.

Alan Cassels notes that disease mongering advertisements for cholesterol-lowering drugs, such as for Pfizer's Lipitor, hype the risk of heart attacks for those people with 'high' cholesterol.